

**Baxter****INFUVITE® ADULT****Multiple Vitamins  
for Infusion****For intravenous infusion  
after dilution only.****Description**

**INFUVITE ADULT** is a sterile product consisting of two 5 mL single-dose vials labeled Vial 1 and Vial 2.

**Each 5 mL of Vial 1 contains:**

Ascorbic acid (Vitamin C) .....	200 mg
Vitamin A* (as palmitate) .....	3,300 IU
Vitamin D <sub>3</sub> * (cholecalciferol) .....	200 IU
Thiamine (Vitamin B <sub>1</sub> ) (as the hydrochloride) .....	6 mg
Riboflavin (Vitamin B <sub>2</sub> ) (as riboflavin 5-phosphate sodium) .....	3.6 mg
Pyridoxine HCl (Vitamin B <sub>6</sub> ) .....	6 mg
Niacinamide .....	40 mg
Dexpanthenol (as <i>D</i> -pantothenyl alcohol) .....	15 mg
Vitamin E* ( <i>dl</i> - $\alpha$ -tocopheryl acetate) .....	10 IU
Vitamin K <sub>1</sub> * .....	150 mcg

Inactive ingredients: 1.4% polysorbate 80, sodium hydroxide and/or hydrochloric acid for pH adjustment, and water for injection.

\*Polysorbate 80 is used to water solubilize the oil-soluble vitamins A, D, E, and K.

**Each 5 mL of Vial 2 contains:**

Folic acid .....	600 mcg
Biotin .....	60 mcg
Vitamin B <sub>12</sub> (cyanocobalamin) .....	5 mcg
Inactive ingredients: 30% propylene glycol, citric acid and/or sodium citrate for pH adjustment, and water for injection.	

**“Aqueous” multiple vitamin preparation for intravenous infusion:**

**INFUVITE ADULT** (Multiple Vitamins for Infusion) makes available a combination of important oil-soluble and water-soluble vitamins in an aqueous solution, formulated for incorporation into intravenous solutions. The liposoluble vitamins A, D, E, and K have been solubilized in an aqueous medium with polysorbate 80, permitting intravenous administration of these vitamins.

Contains no more than 70 mcg/L of aluminum (combined Vials 1 and 2).

**Indications and Usage**

**INFUVITE ADULT** is indicated as a daily multivitamin maintenance supplement for adults and children aged 11 and older receiving parenteral nutrition.

**INFUVITE ADULT** is also indicated in other situations where administration by the intravenous route is required. Such situations include surgery, extensive burns, fractures and other trauma, severe infectious diseases, and comatose states, which may provoke a “stress” situation with profound alterations in the body’s metabolic demands and consequent tissue depletion of nutrients.

The physician should not await the development of clinical signs of vitamin deficiency before initiating vitamin therapy.

**INFUVITE ADULT** (administered in intravenous fluids under proper dilution) contributes intake of necessary vitamins toward maintaining the body’s normal resistance and repair processes.

Patients with multiple vitamin deficiencies or with markedly increased requirements may be given multiples of the daily dosage for two or more days, as indicated by the clinical status.

Some patients do not maintain adequate levels of certain vitamins when a multiple vitamin preparation, such as **INFUVITE ADULT**, in recommended amounts, is the sole source of vitamins. Blood levels of vitamins A, C, D, and folic acid may decline in patients receiving parenteral multivitamins as their sole source of vitamins for 4 to 6 months. Therefore, in patients for whom total parenteral nutrition will be continued for long periods of time blood vitamin concentrations should be monitored to ensure maintenance of adequate levels. If deficiencies appear to be developing, multiples of the formulation (1.5 to 3 times) may be needed for a period of time. When multiples of the formulation are used for more than a few weeks, vitamins A and D should be monitored occasionally to be certain that an excess accumulation of these vitamins is not occurring.

**Contraindications**

**INFUVITE ADULT** is contraindicated where there is a preexisting hypervitaminosis, or a known hypersensitivity to any of the vitamins or excipients in the product.

Allergic reactions have been known to occur following intravenous administration of thiamine and vitamin K. The formulation is contraindicated prior to blood sampling for detection of megaloblastic anemia, as the folic acid and the cyanocobalamin in the vitamin solution can mask serum deficits.

**Warnings**

This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solution, which contain aluminum.

Research indicates that patients with impaired kidney function, including premature neonates who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.

**Precautions**

If this formulation is the only source of vitamins for long periods of time, blood concentration of each of the vitamins should be monitored, particularly vitamins A, C, D, and folic acid, to determine if deficiencies are occurring. If deficiencies are developing or when long-standing vitamin deficiencies are present, it may be necessary to add therapeutic amounts of certain vitamins to supplement the maintenance vitamins provided in **INFUVITE ADULT**.

**Drug – Drug/Solution Interactions: Caution should be exercised when administering INFUVITE ADULT to patients on warfarin sodium-type anticoagulant therapy. In such patients, vitamin K may antagonize the hypoprothrombinemic response to anticoagulant drugs, such as warfarin and its congeners. Therefore, periodic monitoring of prothrombin/INR response is essential in determining the appropriate dosage of anticoagulant therapy.**

**INFUVITE ADULT** (Multiple Vitamins for Infusion) is not physically compatible with alkaline solutions or moderately alkaline drugs such as acetazolamide, chlorothiazide sodium, aminophylline or sodium bicarbonate. Tetracycline HCl and ampicillin may not be physically compatible with **INFUVITE ADULT**. Also, it has been reported that folic acid is unstable in the presence of calcium salts such as calcium gluconate. Direct addition to intravenous fat emulsions is not recommended. Consult appropriate references for listings of physical compatibility of solutions and drugs with the vitamin infusion. In such circumstances, admixture or Y-site administration with vitamin solutions should be avoided.

A number of interactions between vitamins and drugs have been reported which may affect the metabolism of either agent. The following are examples of these types of interactions.

Folic acid may lower the serum concentration of phenytoin resulting in increased seizure activity. Conversely, phenytoin may decrease serum folic acid concentrations and, therefore, should be avoided in pregnancy. Folic acid may decrease the patient’s response to methotrexate therapy.

Pyridoxine may decrease the efficacy of levodopa by increasing its metabolism. Concomitant administration of hydralazine or isoniazid may increase pyridoxine requirements.

In patients with pernicious anemia, the hematologic response to vitamin B<sub>12</sub> therapy may be inhibited by concomitant administration of chloramphenicol.

Several vitamins have been reported to decrease the activity of certain antibiotics. Thiamine, riboflavin, pyridoxine, niacinamide, and ascorbic acid have been reported to decrease the antibiotic activity of erythromycin, kanamycin, streptomycin, doxycycline, and lincomycin. Bleomycin is inactivated *in vitro* by ascorbic acid and riboflavin.

Vitamin K may antagonize the hypoprothrombinemic effect of oral anticoagulants (*see bolded statement above*).

Consult appropriate references for additional specific vitamin-drug interactions.

Some of the vitamins in **INFUVITE ADULT** may react with vitamin K bisulfite or sodium bisulfite; if bisulfite solutions are necessary, patients should be monitored for vitamin A and thiamine deficiencies.

**Drug-Laboratory Test Interactions:**

Ascorbic acid in the urine may cause false negative urine glucose determinations.

*Carcinogenesis, Mutagenesis, and Impairment of Fertility:* Carcinogenicity, mutagenicity, and fertility studies have not been performed with **INFUVITE ADULT**.

**Pregnancy: Pregnancy Category C:**

Animal reproduction studies have not been conducted with **INFUVITE ADULT** (Multiple Vitamins for Infusion). **INFUVITE ADULT** should be given to a pregnant woman only if clearly needed. Pregnant women should follow the U.S. Recommended Daily Allowances for their condition, because their vitamin requirements may exceed those of nonpregnant women. The use of **INFUVITE ADULT** has not been studied in human pregnancy.

**Nursing Mothers:** Lactating women should follow the U.S. Recommended Daily Allowances for their condition, because their vitamin requirement may exceed those of nonlactating women. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when **INFUVITE ADULT** is administered to a nursing mother.

**Pediatric Use:** Safety and effectiveness in children below the age of 11 years have not been established.

**Adverse Reactions**

There have been rare reports of anaphylactic reactions following parenteral multivitamin administration. Rare reports of anaphylactoid reactions have also been reported following large intravenous doses of thiamine. However, the risk is negligible if thiamine is coadministered with other vitamins of the B group.

There have been rare reports of the following types of reactions:

Dermatologic – rash, erythema, pruritis

CNS – headache, dizziness, agitation, anxiety

Ophthalmic – diplopia

Allergic – urticaria, shortness of breath, wheezing and angioedema.

**Overdosage**

The fat-soluble vitamins A, D, and E can accumulate to harmful levels. The possibility of hypervitaminosis A or D should be borne in mind. Clinical manifestations of hypervitaminosis A have been reported in patients with renal failure receiving 1.5 mg/day retinol. Therefore, vitamin A supplementation of renal failure patients should be undertaken with caution.

Water-soluble vitamins are readily excreted in the urine. Treatment of vitamin overdosage usually consists of withdrawal of the vitamin.

**Dosage and Administration**

**INFUVITE ADULT** is ready for immediate use in adults and children aged 11 years and older when added to intravenous infusion fluids.

**INFUVITE ADULT** should not be given as a direct, undiluted intravenous injection as it may give rise to dizziness, faintness, and possible tissue irritation.

**For intravenous feeding, one daily dose of INFUVITE ADULT (5 mL of Vial 1 plus 5 mL of Vial 2) added directly to not less than 500 mL, and preferably 1,000 mL, of intravenous dextrose, saline or similar infusion solutions. Discard any unused portion.**

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

After **INFUVITE ADULT** is diluted in an intravenous infusion, the resulting solution should be refrigerated unless it is to be used immediately. The solution should be used within 24 hours after dilution. Some of the vitamins in this product, particularly A, D, and riboflavin, are light sensitive, therefore, exposure to light should be minimized.

**How Supplied**

**INFUVITE ADULT** – NDC 54643-5649-1, is available in boxes containing 10 vials - 5 each of Vial 1 (5 mL) and Vial 2 (5 mL), one Vial 1 plus one Vial 2 to be used for a single dose.

**Store under refrigeration, 2-8°C (36-46°F).**

**Rx only**

Manufactured by  
**Sandoz Canada Inc.**  
145 Jules-Leger Street  
Boucherville, QC, Canada J4B 7K8


Distributed by  
**Baxter Healthcare Corporation**  
Clintec Nutrition Division  
Deerfield, IL 60015 USA

Printed in Canada

**D1006230**

Rev. September 2007

© INFUVITE is a registered trademark of **Sandoz Canada Inc.**

 CCL LABEL <small>CCL GRAPHIQUES APEX INC. CANADA</small>	<b>ÉPREUVES DE L'IMPRIMEUR / VENDOR'S PROOF</b>
NOM DU PRODUIT / PRODUCT NAME: INFUVITE ADULT NUMÉRO DU PRODUIT / PRODUCT NUMBER: D1006230 N° CODE À BARRES / BARCODE NO.: 6230	DATE: _____ SIGNATURE: _____  APPROBATION / APPROVAL SANDOZ
<b>SPECIFICATIONS</b>  TYPE DE PAPIER / PAPER TYPE: ALLIANCE POIDS DU PAPIER / PAPER WEIGHT: 30 LB, 60 M DIMENSIONS (MM): À PLAT / FLAT: 136 X 296 MM PLIÉ / FOLDED: N/A  POINTS DE COLLE / GLUE SPOTS: N/A FEUILLET PLIÉ / FOLDED LEAFLET: <input checked="" type="checkbox"/> ANGLAIS / ENGLISH VISIBLE <input type="checkbox"/> FRANÇAIS / FRENCH VISIBLE <input type="checkbox"/> AUTRE / OTHER VISIBLE	COULEUR(S) / COLOR(S): #1 <span style="background-color: #0000FF; color: white; padding: 2px;">F</span> <span style="background-color: #0000FF; color: white; padding: 2px;">B</span> PMS 287
	APP.: _____ DATE: _____ APP.: _____ DATE: _____ APP.: _____ DATE: _____

**Baxter**

# INFUVITE® ADULT PHARMACY BULK PACKAGE

## Multiple Vitamins for Infusion

### Rx Only

**For intravenous infusion after  
dilution only.**

## Pharmacy Bulk Package Not for Direct Infusion

### Description

**INFUVITE ADULT (PHARMACY BULK PACKAGE)** is a sterile product consisting of 2 vials – 1 each of Vial 1 (50 mL) and Vial 2 (50 mL Fill in 100 mL Vial), provided as a pharmacy bulk package.

A pharmacy bulk package is a container of a sterile preparation for parenteral use that contains many single doses. The contents are intended for use in a pharmacy admixture program and are restricted to the preparation of admixtures for intravenous infusion.

#### Each 5 mL of Vial 1 contains:

Ascorbic acid (Vitamin C) . . . . .	.200 mg
Vitamin A* (as palmitate) . . . . .	3,300 IU
Vitamin D <sub>3</sub> * (cholecalciferol) . . . . .	.200 IU
Thiamine (Vitamin B <sub>1</sub> ) (as the hydrochloride) . . . . .	.6 mg
Riboflavin (Vitamin B <sub>2</sub> ) (as riboflavin 5-phosphate sodium) . . . . .	3.6 mg
Pyridoxine HCl (Vitamin B <sub>6</sub> ) . . . . .	.6 mg
Niacinamide . . . . .	.40 mg
Dexpanthenol (as D-α-pantothenyl alcohol) . . . . .	.15 mg
Vitamin E* (dl-α-tocopheryl acetate) . . . . .	.10 IU
Vitamin K <sub>1</sub> * . . . . .	.150 mcg

Inactive ingredients: 1.4% polysorbate 80, sodium hydroxide and/or hydrochloric acid for pH adjustment, and water for injection.

\* Polysorbate 80 is used to water solubilize the oil-soluble vitamins A, D, E, and K.

#### Each 5 mL of Vial 2 contains:

Folic acid . . . . .	.600 mcg
Biotin . . . . .	.60 mcg
Vitamin B <sub>12</sub> (cyanocobalamin) . . . . .	.5 mcg

Inactive ingredients: 30% propylene glycol, citric acid and/or sodium citrate for pH adjustment, and water for injection.

#### “Aqueous” multiple vitamin preparation for intravenous infusion:

**INFUVITE ADULT (PHARMACY BULK PACKAGE)** (Multiple Vitamins for Infusion) makes available a combination of important oil-soluble and water-soluble vitamins in an aqueous solution, formulated for incorporation into intravenous solutions. The liposoluble vitamins A, D, E, and K have been solubilized in an aqueous medium with polysorbate 80, permitting intravenous administration of these vitamins.

Contains no more than 70 mcg/L of aluminum (combined Vials 1 and 2).

### Indications and Usage

**INFUVITE ADULT (PHARMACY BULK PACKAGE)** is indicated as a daily multivitamin maintenance supplement for adults and children aged 11 and older receiving parenteral nutrition.

**INFUVITE ADULT (PHARMACY BULK PACKAGE)** is also indicated in other situations where administration by the intravenous route is required. Such situations include surgery, extensive burns, fractures and other trauma, severe infectious diseases, and comatose states, which may provoke a “stress” situation with profound alterations in the body’s metabolic demands and consequent tissue depletion of nutrients.

The physician should not await the development of clinical signs of vitamin deficiency before initiating vitamin therapy.

**INFUVITE ADULT (PHARMACY BULK PACKAGE)** (administered in intravenous fluids under proper dilution) contributes intake of necessary vitamins toward maintaining the body’s normal resistance and repair processes.

Patients with multiple vitamin deficiencies or with markedly increased requirements may be given multiples of the daily dosage for two or more days, as indicated by the clinical status.

Some patients do not maintain adequate levels of certain vitamins when a multiple vitamin preparation, such as **INFUVITE ADULT (PHARMACY BULK PACKAGE)**, in recommended amounts, is the sole source of vitamins. Blood levels of vitamins A, C, D, and folic acid may decline in patients receiving parenteral multivitamins as their sole source of vitamins for 4 to 6 months. Therefore, in patients for whom total parenteral nutrition will be continued for long periods of time blood vitamin concentrations should be monitored to ensure maintenance of adequate levels. If deficiencies appear to be developing, multiples of the formulation (1.5 to 3 times) may be needed for a period of time. When multiples of the formulation are used for more than a few weeks, vitamins A and D should be monitored occasionally to be certain that an excess accumulation of these vitamins is not occurring.

### Contraindications

**INFUVITE ADULT (PHARMACY BULK PACKAGE)** is contraindicated where there is a preexisting hypervitaminosis, or a known hypersensitivity to any of the vitamins or excipients in the product.

Allergic reactions have been known to occur following intravenous administration of thiamine and vitamin K. The formulation is contraindicated prior to blood sampling for detection of megaloblastic anemia, as the folic acid and the cyanocobalamin in the vitamin solution can mask serum deficits.

### Warnings

This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solution, which contain aluminum.

Research indicates that patients with impaired kidney function, including premature neonates who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.

### Precautions

If this formulation is the only source of vitamins for long periods of time, blood concentration of each of the vitamins should be monitored, particularly vitamins A, C, D, and folic acid, to determine if deficiencies are occurring. If deficiencies are developing or when long-standing vitamin deficiencies are present, it may be necessary to add therapeutic amounts of certain vitamins to supplement the maintenance vitamins provided in **INFUVITE ADULT (PHARMACY BULK PACKAGE)**.

#### Drug – Drug/Solution Interactions:

**Caution should be exercised when administering INFUVITE ADULT (PHARMACY BULK PACKAGE) to patients on warfarin sodium-type anticoagulant therapy. In such patients, vitamin K may antagonize the hypoprothrombinemic response to anticoagulant drugs, such as warfarin and its congeners. Therefore, periodic monitoring of prothrombin/INR response is essential in determining the appropriate dosage of anticoagulant therapy.**

**INFUVITE ADULT (PHARMACY BULK PACKAGE)** (Multiple Vitamins for Infusion) is not physically compatible with alkaline solutions or moderately alkaline drugs such as acetazolamide, chlorothiazide sodium, aminophylline or sodium bicarbonate. Tetracycline HCl and ampicillin may not be physically compatible with **INFUVITE ADULT (PHARMACY BULK PACKAGE)**. Also, it has been reported that folic acid is unstable in the presence of calcium salts such as calcium gluconate. Direct addition to intravenous fat emulsions is not recommended. Consult appropriate references for listings of physical compatibility of solutions and drugs with the vitamin infusion. In such circumstances, admixture or Y-site administration with vitamin solutions should be avoided.

A number of interactions between vitamins and drugs have been reported which may affect the metabolism of either agent. The following are examples of these types of interactions.

Folic acid may lower the serum concentration of phenytoin resulting in increased seizure activity. Conversely, phenytoin may decrease serum folic acid concentrations and, therefore, should be avoided in pregnancy. Folic acid may decrease the patient’s response to methotrexate therapy.

Pyridoxine may decrease the efficacy of levodopa by increasing its metabolism. Concomitant administration of hydralazine or isoniazid may increase pyridoxine requirements.

In patients with pernicious anemia, the hematologic response to vitamin B<sub>12</sub> therapy may be inhibited by concomitant administration of chloramphenicol.

FPO



Several vitamins have been reported to decrease the activity of certain antibiotics. Thiamine, riboflavin, pyridoxine, niacinamide, and ascorbic acid have been reported to decrease the antibiotic activity of erythromycin, kanamycin, streptomycin, doxycycline, and lincomycin. Bleomycin is inactivated *in vitro* by ascorbic acid and riboflavin.

Vitamin K may antagonize the hypoprothrombinemic effect of oral anticoagulants (see **bolded statement above**).

Consult appropriate references for additional specific vitamin-drug interactions.

Some of the vitamins in **INFUVITE ADULT (PHARMACY BULK PACKAGE)** may react with vitamin K bisulfite or sodium bisulfite; if bisulfite solutions are necessary, patients should be monitored for vitamin A and thiamine deficiencies.

#### Drug-Laboratory Test Interactions:

Ascorbic acid in the urine may cause false negative urine glucose determinations.

#### Carcinogenesis, Mutagenesis, and Impairment of Fertility:

Carcinogenicity, mutagenicity, and fertility studies have not been performed with **INFUVITE ADULT (PHARMACY BULK PACKAGE)**.

#### Pregnancy: Pregnancy Category C:

Animal reproduction studies have not been conducted with **INFUVITE ADULT (PHARMACY BULK PACKAGE)** (Multiple Vitamins for Infusion). **INFUVITE ADULT (PHARMACY BULK PACKAGE)** should be given to a pregnant woman only if clearly needed. Pregnant women should follow the U.S. Recommended Daily Allowances for their condition, because their vitamin requirements may exceed those of nonpregnant women. The use of **INFUVITE ADULT (PHARMACY BULK PACKAGE)** has not been studied in human pregnancy.

#### Nursing Mothers:

Lactating women should follow the U.S. Recommended Daily Allowances for their condition, because their vitamin requirement may exceed those of nonlactating women. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when **INFUVITE ADULT (PHARMACY BULK PACKAGE)** is administered to a nursing mother.

**Pediatric Use:** Safety and effectiveness in children below the age of 11 years have not been established.

## Adverse Reactions

There have been rare reports of anaphylactic reactions following parenteral multivitamin administration. Rare reports of anaphylactoid reactions have also been reported following large intravenous doses of thiamine. However, the risk is negligible if thiamine is coadministered with other vitamins of the B group.

There have been rare reports of the following types of reactions:

Dermatologic – rash, erythema, pruritis

CNS – headache, dizziness, agitation, anxiety

Ophthalmic – diplopia

Allergic – urticaria, shortness of breath, wheezing and angioedema.

## Overdosage

The fat-soluble vitamins A, D, and E can accumulate to harmful levels. The possibility of hypervitaminosis A or D should be borne in mind. Clinical manifestations of hypervitaminosis A have been reported in patients with renal failure receiving 1.5 mg/day retinol. Therefore, vitamin A supplementation of renal failure patients should be undertaken with caution.

Water-soluble vitamins are readily excreted in the urine. Treatment of vitamin overdosage usually consists of withdrawal of the vitamin.

## Dosage and Administration

**INFUVITE ADULT (PHARMACY BULK PACKAGE)** is ready for immediate use in adults and children aged 11 years and older when added to intravenous infusion fluids.

**INFUVITE ADULT (PHARMACY BULK PACKAGE)** should not be given as a direct, undiluted intravenous injection as it may give rise to dizziness, faintness, and possible tissue irritation.

**Preparation of INFUVITE ADULT (PHARMACY BULK PACKAGE) for intravenous feeding should be done by transferring the contents of Vial 1 into the contents of Vial 2 to provide ten 10 mL single doses. One daily 10 mL dose should be added directly to not less than 500 mL, and preferably 1000 mL, of intravenous dextrose, saline or similar infusion solutions. Discard any unused portion.**

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

After **INFUVITE ADULT (PHARMACY BULK PACKAGE)** is diluted in an intravenous infusion, the resulting solution should be refrigerated unless it is to be used immediately. The solution should be used within 24 hours after dilution. Some of the vitamins in this product, particularly A, D and riboflavin, are light sensitive; therefore, exposure to light should be minimized.

Once closure system has been compromised, withdrawal of container contents should be completed within 4 hours.

**INFUVITE ADULT (PHARMACY BULK PACKAGE)** IS A PHARMACY BULK PACKAGE. IT IS NOT INTENDED FOR DIRECT INFUSION. DISCARD UNUSED PORTION.

## Directions For Dispensing From Pharmacy Bulk Vial

The Pharmacy Bulk Vial is intended for single puncture, multiple dispensing and for intravenous use only. The contents are intended for use in a pharmacy admixture program and are restricted to the preparation of admixtures for infusion. The Pharmacy Bulk Package is to be used only in a suitable work area such as a laminar flow hood (or an equivalent clean air compounding area). Dispensing from Pharmacy Bulk Vial should be completed as soon as possible after initial entry.

## How Supplied

### INFUVITE ADULT (PHARMACY BULK PACKAGE) –

NDC 54643-5650-2, is available in boxes containing 2 vials – 1 each of Vial 1 (50 mL) and Vial 2 (50 mL Fill in 100 mL Vial). Mix contents of Vial 1 with Vial 2 to provide 10 single doses.

**Store under refrigeration, 2-8°C (36-46°F).**



Manufactured by  
**Sandoz Canada Inc.**  
145 Jules-Léger Street  
Boucherville, Qc, Canada, J4B 7K8

Distributed by  
**Baxter Healthcare Corporation**  
Clintec Nutrition Division  
Deerfield, IL 60015 USA

Printed in Canada

D46082006

Rev. March 2012

ParmaCode: 8153

© INFUVITE is a registered trademark of **Sandoz Canada Inc.**





GRAPHIC DESIGNER/GRAPHISTE	Trudy Dussault
COORDINATOR/COORDONNATRICE	Johanne Leclerc
OLD PRODUCT NUMBER/VIEX NUMÉRO PRODUIT	D1006814
NEW PRODUCT NUMBER/NOUVEAU NUMÉRO PRODUIT	D46082006
PHARMA CODE	8153
FILE NAME/NOM DOSSIER	Feuillet Infuvite Adult Baxter-D46082006.qxd
PACKAGING SUPPLIERS/FOURNISSEURS PACKAGING	CCL
PMS COLORS/COULEURS PMS	Bleu

**INSTRUCTIONS**  
**PRODUCTION ART/INFOGRAPHIE**

(recto/front): ..... PMS 287  
 (verso/back): ..... PMS 287  
 dimensions (mm): à plat/flat: ..... 136 X 296  
 plié/folded: ..... N/A

**Sandoz Canada production files are not built with trapping.**

**Les fichiers de production de Sandoz Canada  
 ne sont pas conçus avec le chevauchement des couleurs.**

Created By: Baxter 03/16/12
RA Approval:
PV Approval: